Sign inCreate account

Report workspace tools

NCT06574360RECRUITINGanonymous

Dual Modulation of Sigma-1 and NMDA Receptors in the Treatment of Schizophrenia

Sponsor

Source record

China Medical University Hospital

Phase

Source record

Phase 2

Modality

AI-normalized

small molecule

Target

AI-normalized

Schizophrenia

Indication / condition

AI-normalized

Schizophrenia

Intervention

Source record

S1RA plus NMDAE, S1RA plus Placebo Cap

Source & freshness

Source record

NCT ID

NCT06574360

Original source

ClinicalTrials.gov

Source last updated

Mar 24, 2026

Ingested at

May 23, 2026

Internal sync

Jun 05, 2026

Model version

trialsignal-ai-v1

Normalized confidence

88%

Validation status

validated

Open original registry record
View original source fields

NCT ID

NCT06574360

Title

Dual Modulation of Sigma-1 and NMDA Receptors in the Treatment of Schizophrenia

Sponsor

China Medical University Hospital

Status

RECRUITING

Phase

Phase 2

Condition raw

Schizophrenia

Condition normalized

Schizophrenia

Modality raw

Schizophrenia

Modality normalized

small molecule

Target raw

Schizophrenia

Target normalized

Schizophrenia

Interventions

S1RA plus NMDAE, S1RA plus Placebo Cap

Public preview

Source record

This clinical trial investigates the efficacy of a dual treatment approach combining a sigma-1 receptor agonist (S1RA) with an NMDA enhancer (NMDAE) for patients with treatment-resistant schizophrenia. The study aims to determine if this combination is more effective than S1RA alone, addressing a significant unmet need in schizophrenia treatment.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Full protocol, outcomes, eligibility, contacts and results sections
Patent/IP landscape with verified records when available
Board-ready PDF export with source provenance
Save to folders and synthesize multiple assets in premium workspace
Create account
Sign in

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

Dual Modulation of Sigma-1 and NMDA Receptors in the Treatment of Schizophrenia

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 13, 2026

NCT ID

NCT06574360

Status

RECRUITING

Phase

Phase 2

Sponsor

China Medical University Hospital

Executive brief

Investment-Ready Snapshot

This clinical trial investigates the efficacy of a dual treatment approach combining a sigma-1 receptor agonist (S1RA) with an NMDA enhancer (NMDAE) for patients with treatment-resistant schizophrenia. The study aims to determine if this combination is more effective than S1RA alone, addressing a significant unmet need in schizophrenia treatment.

Source & freshness

Provenance

SourceClinicalTrials.gov
Source updatedMar 24, 2026
Internal syncJun 05, 2026
Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT06574360

Indication

Schizophrenia

Modality

small molecule

Target

Schizophrenia

Intervention

S1RA plus NMDAE, S1RA plus Placebo Cap

Source record

Protocol Description

Detailed source ingestion pending.

Source record

Outcome Measures

Detailed source ingestion pending.

Source record

Eligibility

Detailed source ingestion pending.

AI analysis

Known Results And Readout Context

Detailed source ingestion pending.

IP intelligence

Patent And IP Landscape

Detailed source ingestion pending.

Source record

Contacts

Detailed source ingestion pending.